Thursday, July 9, 2026

Drug profile · INN

florbetaben f-18

florbetaben f-18 (NEURACEQ) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — florbetaben f-18
US status
approved
Class
Route
INTRAVENOUS
Patents
0
Programs
6
Data quality
0.84

Quick answer

florbetaben f-18 (NEURACEQ) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.

Key facts

INN florbetaben f-18
Brand NEURACEQ
Mechanism Diagnostic agent
Route INTRAVENOUS
Formulation SOLUTION

Mechanism of action

Diagnostic agent

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Neuraceq 300 MBq/mL solution for injection Phase 3 · Telethon Foundation · cardiac amyloidosis
  2. WN45443 Phase 3 · HOFFMANN-LA ROCHE · Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia
  3. WN45447 Phase 3 · HOFFMANN-LA ROCHE · Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia
  4. 219867 Phase 2 · GSK Glaxo Smith · Alzheimer's Disease
  5. ACU193-201 Phase 2 · Acumen Pharmaceuticals · Early Alzheimer’s Disease (Mild Cognitive Impairment and Mi
  6. AH0003 Phase 2 · Anaxis Pharma · Alzheimer’s Disease

Frequently asked questions

What is florbetaben f-18?

florbetaben f-18 (NEURACEQ) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.

What is the brand name for florbetaben f-18?

NEURACEQ is a marketed brand name for florbetaben f-18. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of florbetaben f-18?

florbetaben f-18 has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.